Journal article
OS07.2 Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the ARTE trial
Abstract
BACKGROUND: Two phase III trials of bevacizumab (BEV) in newly diagnosed glioblastoma demonstrated prolonged progression-free survival (PFS), but failed to prolong overall survival (OS). Retrospective reports and early phase trials of bevacizumab in glioblastoma patients emphasized that benefit was preferentially seen in frail or elderly patients, but such patients are underrepresented in most clinical trials. Here, we report the outcome of an …
Authors
Wirsching HG; Tabatabai G; Hottinger A; Plasswilm L; Roelcke U; Conen K; Held L; Rushing EJ; Ochsenbein A; Weller M
Journal
Neuro-Oncology, Vol. 19, No. suppl_3, pp. iii13–iii13
Publisher
Oxford University Press (OUP)
Publication Date
May 1, 2017
DOI
10.1093/neuonc/nox036.043
ISSN
1522-8517